This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.

| less than a minute read

Lewis H. Lazarus Discusses McKesson Corporation Derivative Settlement of Opioid Litigation

Lewis H. Lazarus, a partner in the Morris James LLP Corporate and Commercial Litigation Group, discusses with Agenda a recent settlement in a lawsuit accusing directors of McKesson Corporation of failing under Delaware law properly to oversee the company's distribution of opioids. 

Lewis commented, "Governance reforms attached to litigation settlements are far from rare and are viewed by boards as a way to end the burden, expense and distraction associated with litigation." Such reforms tend to be tailored to the allegations, he adds, pointing out that, in the case of McKesson, the complaint emphasized that, while on notice of opioid concerns because of a 2008 settlement, issues continued with some of the same directors on the board.

View full article here. (Subscription Required)

Tags

media mention, bankruptcy committees practice, business torts, corporate governance, corporate trust & fiduciary services, alternative dispute resolution, commercial contract disputes, corporate alternative entity & fiduciary litigation